New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

21

Ardelyx Cutting More Jobs

Disappointed over the “lack of clarity” in the U.S. Food and Drug Administration’s stance on potential approval of the company’s proposed chronic kidney disease (CKD) drug, Ardelyx will cut another 102 jobs, according to an SEC Filing. 

24

Healthcare Marketing: Now & Next

The COVID-19 pandemic altered the trajectory of healthcare, but what about healthcare marketing? As part of its Next series, IPG Health brought together experts from across the network and the industry to talk about the emerging trends and technologies that are accelerating innovation in health. FCB Health Chief Product Officer Graham Johnson discusses a few key trends that marketers should pay attention to in looking toward the future.

26

J&J COVID-19 shot gets better boost from Moderna or Pfizer in NIH study

People who got Johnson & Johnson’s Covid-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer/BioNTech or Moderna, a study run by the National Institutes of Health showed on Oct. 13.

28

FDA approves Keytruda combo for first-line treatment of cervical cancer

The U.S. Food and Drug Administration approved Merck’s anti-PD-1 therapy Keytruda in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test.